Italia markets open in 2 hours 3 minutes

ChemoMetec A/S (0DZ0.L)

LSE - LSE Prezzo differito. Valuta in DKK.
Aggiungi a watchlist
820,000,00 (0,00%)
Alla chiusura: 05:53PM BST
Schermo intero
Chiusura precedente820,00
Aperto791,00
Denaro0,00 x 0
Domanda0,00 x 0
Min-Max giorno732,00 - 759,00
Intervallo di 52 settimane304,00 - 905,00
Volume14.717
Media Volume5.187
Capitalizzazione12,07B
Beta (mensile su 5 anni)1,30
Rapporto PE (ttm)1,09
EPS (ttm)7,55
Prossima data utili11 set 2024
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Notification of managers’ transactions

    ANNOUNCEMENT NO. 244 14 September 2023 Notification of managers’ transactions ChemoMetec A/S has received the enclosed notification pursuant to Article 19 of EU Regulation no. 596/2014 of transactions related to shares in ChemoMetec A/S made by persons discharging managerial responsibilities in ChemoMetec A/S and/or persons closely associated with them. See the transactions of CEO Rasmus Kofoed in the attached PDF document. For further information, please contact: Niels Høy Nielsen, CFOTelephone

  • GlobeNewswire

    Annual Report 2022/23 - Continued solid earnings, but weaker growth amid challenging market conditions

    ANNOUNCEMENT NO. 243 13 September 2023 Annual Report 2022/23 (1 July 2022 - 30 June 2023) Continued solid earnings, but weaker growth amid challenging market conditions ChemoMetec’s revenue for 2022/23 grew by 4% to DKK 442.3 million and operating profit (EBITDA) for 2022/23 was DKK 251.0 million, a 13% increase on 2021/22. In 2022/23, ChemoMetec continued developing the new Xcyto platform and the instruments XcytoMatic 40 and XcytoMatic 30. In addition to the XcytoMatic instruments, we expect t

  • GlobeNewswire

    Guidance for the 2023/24 financial year

    ANNOUNCEMENT NO. 242 13 September 2023 Guidance for the 2023/24 financial year ChemoMetec has today approved the annual report for 2022/23, including the guidance for 2023/24, which is considered inside information. For 2023/24, ChemoMetec expects revenue in the range of DKK 400-435 million (2022/23: DKK 442.3 million) and EBITDA in the range of DKK 200-220 (2022/23: DKK 251.0 million). The annual report for 2022/23, which is released along with this announcement, sets out the underlying assumpt